Trials / Completed
CompletedNCT04870177
Study of AK112 in the Treatment of Advanced Gynecological Tumors
Phase II Study of AK112 (Anti-PD-1 and VEGF Bi-specific Antibody) in the Treatment of Advanced Gynecological Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Akeso · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK112 | AK112 infusion biweekly |
Timeline
- Start date
- 2021-04-09
- Primary completion
- 2024-05-10
- Completion
- 2024-05-10
- First posted
- 2021-05-03
- Last updated
- 2025-02-28
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04870177. Inclusion in this directory is not an endorsement.